The ASAM Criteria—the American Society of Addiction Medicine’s guidelines for addiction treatment—are not just a tool for program administrators and insurance bureaucrats. They provide a useful conceptual framework for thinking about your patients and what kind of care they need.
Find out what the FDA’s Risk Evaluation and Mitigation Strategies (REMS) program focusing on extended-release and long-acting opioid analgesic medications is all about, in an interview with Edwin A. Salsitz, MD.
Learn how you can use The ASAM Criteria to determine what kind of care a patient with an addiction needs and help ensure funding for that treatment, in an interview with David Mee-Lee, MD.
Today’s conversation about “smart drugs” is fundamentally different and refers to the use of medications by people without psychiatric disorders who seek a boost or cognitive edge.
Americans guzzled a mind-blowing 3.5 billion energy drinks in 2013, with sales totaling $8.7 billion. But what, exactly, are energy drinks? Do they actually give you energy? And are they safe?
Get insight into the problem of malingering—in other words faking—ADHD symptoms by patients who may want to receive academic accommodations or obtain prescription stimulants, in an interview with researcher Mandi Musso, PhD.
Learn some of the key best practices that can help you work with patients in substance abuse treatment who also have a traumatic brain injury, in an interview with Duane Reynolds, LSW, LADC, associate director of the Vinland National Center in Minnesota.
Find out more about how you can evaluate and treat ADHD symptoms in patients with addiction, in an interview with clinical neuropsychologist Christopher B. Mertz.
In today's episode, Dr. Brian Hurley provides expert insights into the current state of stimulant use disorder, its implications across different regions, and available...